{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:12:33Z","timestamp":1770995553390,"version":"3.50.1"},"reference-count":15,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ocular Immunology and Inflammation"],"published-print":{"date-parts":[[2024,11,25]]},"DOI":"10.1080\/09273948.2024.2404515","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T19:55:29Z","timestamp":1726516529000},"page":"2594-2596","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Bilateral Panuveitis After Endometrial Cancer Treatment with Dostarlimab: A Case Report"],"prefix":"10.1080","volume":"32","author":[{"given":"Jacobo Emilio","family":"Enr\u00edquez-Fuentes","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Lorenzo-Castro","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Antonio","family":"Pascual-Santiago","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Colino-Gallardo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Arriola-Villalobos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01539-5"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12081031"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.05.016"},{"key":"e_1_3_4_5_1","unstructured":"Food & Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer [media release]. https:\/\/www.fda.gov\/drugs. Accessed April 22 2021."},{"key":"e_1_3_4_6_1","unstructured":"GlaxoSmithKline. Jemperli (dostarlimab): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761174s000lbl.pdf."},{"key":"e_1_3_4_7_1","unstructured":"GlaxoSmithKline. European Commission approves GSK\u2019s JEM- PERLI (dostarlimab) the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer [media release]. https:\/\/www.gsk.com. Accessed April 23 2021."},{"key":"e_1_3_4_8_1","unstructured":"GlaxoSmithKline. Jemperli (dostarlimab) summary of product characteristics (SmPC). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/jemperli. 2021."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58138"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2021.01.003"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_816_20"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000530"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"}],"container-title":["Ocular Immunology and Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09273948.2024.2404515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:07:19Z","timestamp":1732658839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09273948.2024.2404515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11,25]]}},"alternative-id":["10.1080\/09273948.2024.2404515"],"URL":"https:\/\/doi.org\/10.1080\/09273948.2024.2404515","relation":{},"ISSN":["0927-3948","1744-5078"],"issn-type":[{"value":"0927-3948","type":"print"},{"value":"1744-5078","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ioii20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ioii20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}